Navigation Links
Bionomics Achieves US$1 Million Milestone Payment from Genmab
Date:2/19/2008

ADELAIDE and COPENHAGEN, Feb. 19 /PRNewswire-FirstCall/ -- Bionomics Limited (ASX: BNO, US OTC: BMICY) today announced the successful completion of pre-clinical testing on the first of eight proteins licensed to US $2.6 billion Danish antibody company Genmab A/S (OMX: GEN), triggering a US $1 million milestone payment.

Under the agreement, which was executed in February 2006, Genmab acquired the exclusive worldwide rights to eight proteins identified and characterised by Bionomics using its proprietary Angene(R) angiogenesis platform. Antibodies to these proteins have potential as treatments for cancer and other diseases. At the time of the agreement, Bionomics received an upfront fee and the US $1 million is the first in a series of potential milestone payments upon achieving specified pre-clinical and clinical milestones. Bionomics will also receive milestone payments and royalties on product sales for each product reaching the market.

The US $1 million payment has been triggered with the significant progress made in the first stage of evaluation of the licensed proteins. This evaluation strongly supported the potential of a selection of the licensed proteins as antibody targets and development of a therapy to treat pathological angiogenic conditions. This milestone marks commencement of the next phase of the development program under the collaboration.

"This is a very significant milestone for Bionomics as it validates Bionomics' Angene(R) platform as a source of new treatment modalities for cancer and other conditions involving pathological formation of new blood vessels. It also reinforces for our shareholders the significant commercial potential of our collaboration with Genmab," said CEO of Bionomics Dr. Deborah Rathjen.

"We have been working in close collaboration with Genmab for several years and this latest milestone is a clear validation of the strength of this partnership which aims to bring new antibody-based treatment
'/>"/>

SOURCE Bionomics Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
2. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
3. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
4. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
5. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
6. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
7. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
8. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
9. BioVascular Inc. Closes $10.87 Million Series C Financing
10. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
11. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Antigen Discovery Inc. (ADi), a privately held company ... receipt of a National Institutes of Health (NIH) Phase ... of Dental and Craniofacial Research (NIDCR). The one-year $225,000 ... Microarray Chip, which will contain every protein in all ... the development of safe and effective vaccines and therapies ...
(Date:10/22/2014)... 22, 2014  Paper Pak Industries, a manufacturer ... ® Body Guard Bio, a disposable, highly ... bacteria and virus while protecting service providers and ... features a rugged, external nylon shell, watertight zipper, ... leak-proof inner chamber that contains contaminated and potentially ...
(Date:10/22/2014)... , Oct. 22, 2014  With a vision ... health medications, a Global Pharmaceutical and Biotech manufacturer ... technology and turnkey solution to protect their animal ... http://photos.prnewswire.com/prnh/20141021/153438 Photo - ... was serialized and aggregated by the Xyntek and ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Xyntek and Antares Serialization Solution Protects Pets Too! 2
... Ventus Medical, Inc. a privately-held medical device company ... breathing, today announced that it has received CE ... (Photo:   http://photos.prnewswire.com/prnh/20110209/SF45785-b ) ... pleased to accomplish this important regulatory milestone. Receiving ...
... Cempra Pharmaceuticals today announced the appointment of David ... well as announcing an expansion of its clinical ... programs, solithromycin and TAKSTA ... significant anti-infective clinical development experience. Solithromycin ...
Cached Medicine Technology:Ventus Medical Receives CE Mark for Provent® Sleep Apnea Therapy 2Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™ 2Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™ 3
(Date:10/25/2014)... global HCIT outsourcing market is forecast to grow at ... 2018 from $35 billion in 2013. The health insurance ... the HCIT outsourcing market. These industries follow the HCIT ... reduce operational and maintenance costs, increase access to IT ... costs), share risk, and quickly implement new technologies. , ...
(Date:10/25/2014)... October 25, 2014 The ... which verifies IT-accessibility for disabled users by disabled ... logo to Mackin Educational Resources of Burnsville, ... management system and to the Minnesota Alliance for ... "Own Best Medicine" website. Both organizations ...
(Date:10/25/2014)... Mesothelioma researchers are reporting extended survival in ... after his combination drug therapy became too toxic. ... posted on the Surviving Mesothelioma website. , A ... Japan suggests that “maintenance therapy” with pemetrexed may be ... tolerate higher doses of cisplatin. , “Although the ...
(Date:10/25/2014)... 2014 (HealthDay News) -- Researchers who discovered antibiotics ... are cause for concern. The use of ... for human consumption contribute to the development of ... background information from the study. Each year ... 2 million people and kill about 23,000, according ...
(Date:10/22/2014)... At a time when the national ... athletes at all levels, the UPMC Sports Medicine ... discussion where two powerful messages are lost: Concussions can ... in full recoveries every day. , In striving to ... and research, UPMC and the Concussion Program are unveiling ...
Breaking Medicine News(10 mins):Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 4Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4
... price hikes in Nepal have irked student organizations who came ... The protestors blocked roads and stoned vehicles and burnt tyres ... commerce minister. The population of Nepal is furious with the ... costlier. ,The student wings of two of the leading ...
... only half of drug- or alcohol-addicted family members seek help ... to 82% of them. ,On interviewing about 902 U.S. ... Drug Addiction poll revealed that a member of their immediate ... ,The findings of the poll were that 51% said their ...
... been affected by bird flu killing thousands of ducks. Health ... infected ducks in from Vietnam. ,Ku Chanthan, a veterinary ... two people were admitted to the hospital on suspicion of ... around 1,300 ducks died from bird flu. Ku added that ...
... Nilambur in Malappuram district of Kerala is all set to ... be Class 4-literate//. Some of the credit would go to ... of that village in the age group 15-50 have not ... , The Kerala State Literacy Mission has organized the ...
... the government health officials, initial clinical trials show that ... ,"Forty-nine healthy people who received the injections ... the vaccine was safe," said Zhang Wei, head of ... Drug Administration (SFDA). ,"The recipients appeared immune ...
... that they say can detect the deadly anthrax in ... they are expensive// and time-consuming. Time is critical because ... ,Professor Peter Seeberger and his team at ... the anthrax surface molecule. They then attached this molecule ...
Cached Medicine News:Health News:Fuel Price Hike Triggers Violent Protests In Nepal 2Health News:Fuel Price Hike Triggers Violent Protests In Nepal 3Health News:Class 4 literacy to be attained by a Kerala village 2Health News:China’s AIDS vaccine-successfully finishes first phas 2
Aire-Cuf® tracheostomy tubes are ideal for short-term to medium-term ventilator support....
... flange tracheostomy tubes are intended ... proper length fixed neck flange ... ,Adjustable neck flange Hyperflex™ ... for both horizontal and vertical ...
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions....
KIMBERLY-CLARK BALLARD Neonatal and Pediatric TRACH CARE Y features lavage/irrigation port and locking thumb port. Multiple French sizes and packaging configurations. Gamma sterilized....
Medicine Products: